1. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015) Authors: Garcia-Manero, G.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Maniar, M. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 222 IS GASTROESOPHAGEAL REFLUX DISEASE MORE PREVALENT IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE?. Issue 1 (1st January 2007) Authors: Singh, J.; Malani, A. K.; Pabla, M.; Vaka, S.; Patel, V.; Gupta, C.; Kambhampati, S. Journal: Journal of investigative medicine Issue: Volume 55:Issue 1(2007) Page Start: S283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 326 DOES HYPERGAMMAGLOBULINEMIA PREDISPOSE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO SECONDARY SOLID TUMORS?. Issue 1 (1st January 2007) Authors: Malani, A.; Singh, J.; Patel, V.; Skikne, B.; Pabla, M.; Vaka, S.; Gupta, C.; Vanveldhuizen, P.; Kambhampati, S. Journal: Journal of investigative medicine Issue: Volume 55:Issue 1(2007) Page Start: S302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?. (April 2015) Authors: Silverman, L.R.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Navada, S.C.; Azarnia, N.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. (12th June 2019) Authors: Mato, A.R.; Schuster, S.J.; Lamanna, N.; Pagel, J.M.; Flinn, I.W.; Barrientos, J.; Reeves, J.A.; Cheson, B.D.; Barr, P.M.; Kambhampati, S.; Lansigan, F.; Pu, J.J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N.M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E.T.; Tsao, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1). (23rd June 2022) Authors: Stein, E.; de Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Warlick, E.; Roth, D.; Kelly, M.; Pollyea, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). (23rd June 2022) Authors: Rifkin, R. M.; Costello, C. L.; Birhiray, R. E.; Kambhampati, S.; Richter, J.; Abonour, R.; Lee, H. C.; Kim, Y. J.; Ren, K.; Stull, D. M.; Cherepanov, D.; Bogard, K.; Noga, S. J.; Girnius, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 837 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS. (23rd June 2022) Authors: Daver, N. G.; Vyas, P.; Kambhampati, S.; Al Malki, M. M.; Larson, R.; Asch, A.; Mannis, G.; Chai-Ho, W.; Tanaka, T.; Bradley, T.; Jeyakumar, D.; Wang, E.; Xing, G.; Chao, M.; Ramsingh, G.; Renard, C.; Lal, I.; Zeidner, J.; Sallman, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. (June 2017) Authors: Sharman, J.P.; Brander, D.M.; Mato, A.; Kambhampati, S.; Burke, J.M.; Lansigan, F.; Schreeder, M.T.; Lunin, S.D.; Ghosh, N.; Zweibach, A.; Shtivelband, M.I.; Travis, P.M.; Chandler, J.; Kolibaba, K.S.; Sporteli, P.; Miskin, H.P.; Weiss, M.S.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗